Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity

12 Jan 2023

Abstract excerpt

A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting deeper depletion of CD20-expressing cells with repeat infusions. We assessed cellular immune profiles and their association with transient disease activity following anti-CD20 initiation as a window into relapsing disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to Multiple Sclerosis Research Studies
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36634138
DOI: 10.1073/pnas.2207291120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activityPMID 36634138Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple SclerosisSemantic proximity Read ↗

Early multiple sclerosis activity associated with TBX21+CD21loCXCR3+ B cell expansion resembling EBV-induced phenotypes.Semantic proximity Read ↗

Single-cell analysis suggests coordinated immune-cell redistribution between blood and cerebrospinal fluid in early multiple sclerosisSemantic proximity Read ↗

Anti-CD20 therapy depletes activated myelin-specific CD8 + T cells in multiple sclerosisSemantic proximity Read ↗

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity Read ↗

B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent FeaturesSemantic proximity Read ↗

Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.Semantic proximity Read ↗

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with OcrelizumabSemantic proximity Read ↗

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration propertiesSemantic proximity Read ↗

Dynamics of spinal fluid immune cell alterations following cladribine tablet treatment in multiple sclerosisSemantic proximity Read ↗

Granzyme B + CD8 + T cells with terminal differentiated effector signature determine multiple sclerosis progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.